Edition:
United States

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

44.49USD
21 Sep 2018
Change (% chg)

$-4.50 (-9.19%)
Prev Close
$48.99
Open
$47.05
Day's High
$47.25
Day's Low
$43.68
Volume
1,629,693
Avg. Vol
345,106
52-wk High
$73.90
52-wk Low
$16.17

Latest Key Developments (Source: Significant Developments)

CRISPR Therapeutics AG Files For Potential Mixed Shelf Offering
Wednesday, 19 Sep 2018 06:00pm EDT 

Sept 19 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AG FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

CRISPR Therapeutics Announces Proposed Public Offering Of Common Shares
Wednesday, 19 Sep 2018 04:08pm EDT 

Sept 19 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.CRISPR THERAPEUTICS AG - COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $200,000,000 OF ITS COMMON SHARES.  Full Article

Crispr Therapeutics, Intellia Therapeutics And Caribou Biosciences Provide Update On U.S Federal Circuit Decision
Monday, 10 Sep 2018 04:30pm EDT 

Sept 10 (Reuters) - Intellia Therapeutics Inc ::CRISPR THERAPEUTICS, INTELLIA THERAPEUTICS AND CARIBOU BIOSCIENCES PROVIDE UPDATE ON U.S FEDERAL CIRCUIT DECISION UPHOLDING THE RULING BY U.S. PATENT AND TRADEMARK OFFICE IN INTERFERENCE PROCEEDING RELATING TO CRISPR/CAS9 GENOME EDITING TECHNOLOGY.INTELLIA THERAPEUTICS INC - COMPANIES EXPECT USPTO WILL CONTINUE TO ISSUE PATENTS TO UC COVERING FOUNDATIONAL CRISPR/CAS9 TECHNOLOGY.  Full Article

Crispr Therapeutics Qtrly ‍​collaboration Revenue $32.3 Mln
Thursday, 8 Mar 2018 04:15pm EST 

March 8 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - QTRLY ‍​COLLABORATION REVENUE $32.3 MILLION VERSUS $2.3 MILLION.  Full Article

Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share
Thursday, 4 Jan 2018 07:03pm EST 

Jan 4 (Reuters) - Crispr Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 5.00 MILLION COMMON SHARES PRICED AT $22.75PER SHARE.  Full Article

Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​
Wednesday, 3 Jan 2018 06:15am EST 

Jan 3 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.CRISPR THERAPEUTICS AG - ‍COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS COMMON SHARES​.  Full Article

Crispr Therapeutics Announces Appointment Of Dr. Rodger Novak As Chairman Of The Board
Thursday, 21 Dec 2017 08:00am EST 

Dec 21 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. RODGER NOVAK AS CHAIRMAN OF THE BOARD.CRISPR THERAPEUTICS AG - ‍RODGER NOVAK WILL SUCCEED TONY COLES​.CRISPR THERAPEUTICS AG - ‍TONY COLES WILL REMAIN A SENIOR ADVISOR TO CRISPR THERAPEUTICS​.  Full Article

Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
Tuesday, 12 Dec 2017 08:30am EST 

Dec 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA.VERTEX PHARMACEUTICALS INC - VERTEX SELECTS CTX001 AS FIRST GENE EDITED TREATMENT TO BE DEVELOPED AS PART OF COLLABORATION WITH CRISPR THERAPEUTICS.VERTEX PHARMACEUTICALS - TRIAL APPLICATION FOR CTX001 SUBMITTED IN EUROPE TO SUPPORT INITIATION OF PHASE 1/2 CLINICAL STUDY IN Β-THALASSEMIA IN 2018.VERTEX PHARMACEUTICALS - IND APPLICATION PLANNED FOR SUBMISSION IN 2018 TO SUPPORT INITIATION OF A PHASE 1/2 TRIAL IN SICKLE CELL DISEASE FOR CTX001.  Full Article

CRISPR Therapeutics Submits First Clinical Trial Application For CRISPR Gene-Edited Therapy, In Β-Thalassemia
Thursday, 7 Dec 2017 07:00am EST 

Dec 7 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS SUBMITS FIRST CLINICAL TRIAL APPLICATION FOR A CRISPR GENE-EDITED THERAPY, CTX001 IN Β-THALASSEMIA.CRISPR THERAPEUTICS AG - ANNOUNCED SUBMISSION OF A CLINICAL TRIAL APPLICATION FOR CTX001 IN Β-THALASSEMIA.CRISPR THERAPEUTICS AG - PHASE 1/2 TRIAL OF CTX001 IS EXPECTED TO BEGIN IN EUROPE IN 2018.CRISPR THERAPEUTICS AG - CO ALSO PLANS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION FOR CTX001 TO TREAT SICKLE CELL DISEASE WITH U.S. FDA IN 2018.  Full Article

CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs
Monday, 13 Nov 2017 05:00am EST 

Nov 13 (Reuters) - CRISPR Therapeutics AG :CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs.‍Under terms, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications​.‍In exchange, CureVac will receive an upfront payment and research funding ​.CRISPR Therapeutics-‍CureVac to also be eligible to receive development, commercial milestones, royalties on commercialized products from collaboration​.  Full Article

CRISPR gene editing can cause risky collateral DNA damage: study

LONDON Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.